phenobarbital has been researched along with Hyperammonemia in 5 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The seizures were controlled by phenobarbital." | 3.88 | [Vomiting associated with weight stagnation and convulsions: urea cycle disorder should be suspected]. ( Abilkacem, R; Agadr, A; Boujrad, S; Hasbaoui, BE, 2018) |
| "Hyperammonemia was defined as a plasma ammonia level exceeding 100 μg/dl with reference to the standard range and previous reports." | 1.39 | Risk factors for hyperammonemia in pediatric patients with epilepsy. ( Imai, K; Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Takahashi, Y; Yamamoto, Y; Yazawa, R, 2013) |
| "To describe the dose-concentration relationship of a continuous intravenous infusion of valproic acid (VPA) in pediatric patients when a dosing protocol is used." | 1.34 | Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. ( Baumann, RJ; Cook, AM; Farzam, F; Kuhn, RJ; Lewis, DA; Taylor, LM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasbaoui, BE | 1 |
| Boujrad, S | 1 |
| Abilkacem, R | 1 |
| Agadr, A | 1 |
| Yamamoto, Y | 1 |
| Takahashi, Y | 1 |
| Imai, K | 1 |
| Mishima, N | 1 |
| Yazawa, R | 1 |
| Inoue, K | 1 |
| Itoh, K | 1 |
| Kagawa, Y | 1 |
| Inoue, Y | 1 |
| Hantson, P | 1 |
| Frederick, A | 1 |
| van Rijckevorsel, K | 1 |
| Gomez-Ibañez, A | 1 |
| Urrestarazu-Bolumburu, E | 1 |
| Viteri-Torres, C | 1 |
| Taylor, LM | 1 |
| Farzam, F | 1 |
| Cook, AM | 1 |
| Lewis, DA | 1 |
| Baumann, RJ | 1 |
| Kuhn, RJ | 1 |
5 other studies available for phenobarbital and Hyperammonemia
| Article | Year |
|---|---|
[Vomiting associated with weight stagnation and convulsions: urea cycle disorder should be suspected].
Topics: Adolescent; Anticonvulsants; Body Weight; Failure to Thrive; Female; Headache; Humans; Hyperammonemi | 2018 |
Risk factors for hyperammonemia in pediatric patients with epilepsy.
Topics: Acetazolamide; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Rela | 2013 |
Hyperammonemic encephalopathy after adjunction of phenobarbital to chronic topiramate and oxcarbazepine therapy.
Topics: Anticonvulsants; Brain Diseases; Carbamazepine; Child; Electroencephalography; Fructose; Humans; Hyp | 2015 |
Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism.
Topics: Drug Synergism; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans; Hyperammonemia; Middl | 2011 |
Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combinatio | 2007 |